Delivery Order 75N91019D00024-75N91020F00032
Award Date
9/25/20
Potential Completion Date
9/18/29
Potential Value
$12M
Federal Agency
National Cancer Institute
Awardee
Leidos Biomedical Research Inc.
Ultimate Awardee
Leidos Holdings, Inc.
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Fort Detrick, MD 21702, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a cost-plus-fixed-fee delivery order contract worth up to $3,332,886.00 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the identification and delivery of clinical drug candidates, with a completion date of September 24, 2025. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) that provides...
This is a cost-plus-fixed-fee delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $992,988.00 contract is for Next Generation Cancer Models (Non CMDC) Molecular Characterization and Clinical Data Collection services. Leidos Biomedical Research Inc. serves as a Federally Funded Research and Development Center (FFRDC) contractor for the NCI,...
This is a federal contract award from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The $2,741,760.00 contract is for the discovery of novel drug combinations for clinical development. The award is a Delivery Order under a larger Indefinite Delivery Contract with a potential value of $6.6 billion over 5 years, establishing Leidos Biomedical Research Inc. as a Federally Funded Research and Development Center (FFRDC)...
This is a $12,149,451.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the elaboration and use of syngeneic pre-clinical models for cancer drug development, with a period of performance through September 15, 2026. This is not a set-aside contract. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for...
This is a $376,353.24 federal contract award issued by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for "BIOEQUIVALENCY STUDIES" and was awarded on September 2, 2016, with a period of performance through March 1, 2019. Leidos Biomedical Research Inc. serves as a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a range of biomedical research and facilities support...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the NCI Federally Funded Research and Development Center (FFRDC) and has a ceiling value of $6,371,084.00. The contract period of performance runs through November 13, 2025. Leidos Biomedical Research Inc. provides a range of biomedical research and facilities support services to federal agencies, with a...
This federal contract award, identified as 75N91019D00024|75N91022F00004, is for a "GS-524 PHASE 1 TRIAL" with an ultimate completion date of July 6, 2026. The contract was awarded on January 7, 2022 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., with a ceiling value of $12,045,876.00. The contract is a delivery order under a Cost Plus Fixed Fee pricing type. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC)...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $439,550 delivery order contract to Leidos Biomedical Research Inc. as the prime contractor. The contract is for work to be performed at Building 539 Room 153 Anteroom at Fort Detrick, Maryland from May 23, 2022 through October 27, 2023. Leidos Biomedical Research Inc. will provide research and development services on a cost plus fixed fee basis to support the National Cancer Institute's...
The U.S. National Cancer Institute (NCI) awarded a Delivery Order worth $11,920,234.00 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the ARPA-H BIOMEDICAL DATA FABRIC TOOLBOX PROGRAM, with an ultimate completion date of December 31, 2027. This award is part of Leidos Biomedical Research Inc.'s single-award Indefinite Delivery Contract with the NCI, valued at up to $6.6 billion over 5 years. The contract is a Cost Plus Fixed Fee arrangement and does...
This contract award, valued at $2,266,630.00, was issued by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for a Delivery Order task, with a cost-plus-fixed-fee pricing type, and a completion date of July 5, 2025. This award is not associated with any set-aside designation. Leidos Biomedical Research Inc. is a provider of research, development, and...